IFOSFAMIDE TREATMENT OF ADVANCED OVARIAN-CANCER

Simple item page
dc.contributor.authorYAZIGI, R
dc.contributor.authorWILD, R
dc.contributor.authorMADRID, J
dc.contributor.authorARRAZTOA, J
dc.date.accessioned2025-01-24T00:10:16Z
dc.date.available2025-01-24T00:10:16Z
dc.date.issued1984
dc.description.abstractTo determine the efficacy of ifosfamide in the treatment of advanced ovarian malignancy, 20 patients with stages III and IV epithelial ovarian cancer were treated with this agent. Of these, 15 received the drug as primary chemotherapy. The response rate was 33%, with a median duration of remission of 13 mo. Five patients were treated with ifosfamide after failure with previous chemotherapy; no responses were seen in this group. Hematuria was observed in 2% of the treatment cycles with the use of the antidote mercapto-ethan-sulfonate acid. Though ifosfamide is an active drug in the treatment of patients with advanced ovarian cancer, it is not superior to traditional single alkylating agents.
dc.fuente.origenWOS
dc.identifier.issn0029-7844
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/102012
dc.identifier.wosidWOS:A1984SA75600006
dc.issue.numero2
dc.language.isoen
dc.pagina.final166
dc.pagina.inicio163
dc.revistaObstetrics and gynecology
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleIFOSFAMIDE TREATMENT OF ADVANCED OVARIAN-CANCER
dc.typeartículo
dc.volumen63
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas